Krishna Institute of Medical Sciences Ltd Q3 FY25 Results
KIMSQ3 FY25 ResultsAnnounced 6 Feb 2025, 05:02 pm| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 772.40 | 0.6% |
| Total Income | 790.20 | 1.0% |
| Expenditure | 655.60 | 5.7% |
| PBT | 134.60 | 17.0% |
| Net Profit | 92.50 | 23.4% |
| OPM | 6.01% | 6.38pp |
| NPM | 11.71% | 3.72pp |
| EPS | 2.22 | 17.2% |
Krishna Institute of Medical Sciences Ltd Reports Q3 and Nine Months FY25 Financial Results: Revenue of INR 790 Cr, EBITDA of INR 205 Cr, and PAT of INR 93 Cr
07 Feb 2025 · 7 Feb 2025, 12:22 am
Summary
Krishna Institute of Medical Sciences Ltd (KIMS Hospitals) reported its unaudited (Standalone & Consolidated) financial results for the 03rd quarter and nine months ended 31st December 2024. The company recorded a Consolidated Revenue of INR 790 Cr, a growth of 29.7% on YoY and 1.0% on QoQ basis. The Consolidated EBITDA stood at INR 205 Cr, a growth of 36.4% on YoY and de-growth of 8.1% on QoQ basis. The EBITDA margin was at 25.9% vs. 24.7% in Q3 FY24 and 28.5% in Q2 FY25. The Consolidated PAT was at INR 93 Cr in Q3 FY25 against INR 77 Cr and INR 121 Cr in Q3 FY24 and Q2 FY25 respectively. The Consolidated EPS for 9 months was INR 7.1 (face value of shares Rs. 2/-), a growth of 15.6% (adjusted for share split) on YoY basis. The Cash and Cash Equivalents stood at INR 112 Cr as on Q3 FY25.
Key Highlights
- 1
Consolidated Revenue of INR 790 Cr, a growth of 29.7% on YoY and 1.0% on QoQ basis.
- 2
Consolidated EBITDA of INR 205 Cr, a growth of 36.4% on YoY and de-growth of 8.1% on QoQ basis.
- 3
EBITDA margin at 25.9% vs. 24.7% in Q3 FY24 and 28.5% in Q2 FY25.
- 4
PAT at INR 93 Cr in Q3 FY25 against INR 77 Cr and INR 121 Cr in Q3 FY24 and Q2 FY25 respectively.
- 5
Consolidated EPS for 9 months of INR 7.1 (face value of shares Rs. 2/-), a growth of 15.6% (adjusted for share split) on YoY basis.
- 6
Cash and Cash Equivalents stood at INR 112 Cr as on Q3 FY25.
Management Comments
Dr. B Bhaskar Rao
CMD, KIMS Hospitals
Despite being a seasonally lean quarter, we have managed growth on key parameters like ARBOB and ARPP on a YoY basis. This has been possible because of our relentless focus on improving operational efficiencies. Going forward, as new units start delivering on all parameters, we are confident of achieving our targets set for FY 25 and beyond.
Informational and educational content only. Not investment advice.